Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413107 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL743122 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL8427873 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL2413105 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL743121 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL743123 | 1.00 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL989536 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL16533210 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL426503 | 0.88 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL9897558 | 0.88 | MAPT (0.46) | CTSLCTSBCTSKNAAAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530521-B2 | Nitrooxy cycloalkane derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME LLC | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | AGTR2, AGTR1, NR3C2 | CTSL 3819/4885CTSB 3764/4885CTSK 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.